What is the appropriate treatment regimen for uncomplicated genital Chlamydia trachomatis infection, including options for pregnant patients and partner treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Chlamydia Treatment

For uncomplicated genital Chlamydia trachomatis infection, treat with doxycycline 100 mg orally twice daily for 7 days as first-line therapy, or azithromycin 1 g orally as a single dose when compliance is uncertain. Both regimens demonstrate equivalent efficacy (97-98% cure rates), but doxycycline is preferred due to lower cost and emerging evidence of superior efficacy for rectal infections 1.

Standard Treatment Regimens

Recommended First-Line Options

  • Doxycycline 100 mg orally twice daily for 7 days 2, 1
  • Azithromycin 1 g orally as a single dose 2, 1

When to choose azithromycin over doxycycline:

  • Compliance concerns or erratic healthcare-seeking behavior
  • Inability to ensure 7-day treatment completion
  • Need for directly observed therapy 1

Alternative Regimens (when first-line options contraindicated)

  • Erythromycin base 500 mg orally four times daily for 7 days
  • Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
  • Ofloxacin 300 mg orally twice daily for 7 days
  • Levofloxacin 500 mg orally once daily for 7 days 2, 1

Important caveat: Erythromycin has lower efficacy and poor tolerability due to gastrointestinal side effects that reduce compliance 1.

Pregnancy-Specific Treatment

Doxycycline and fluoroquinolones (ofloxacin, levofloxacin) are absolutely contraindicated in pregnancy 3, 4.

Recommended for Pregnant Women

  • Azithromycin 1 g orally as a single dose - now considered acceptable based on safety and efficacy data 5
  • Amoxicillin 500 mg orally three times daily for 7 days 3, 6

Alternative for Pregnant Women

  • Erythromycin base 500 mg orally four times daily for 7 days
  • Erythromycin base 250 mg orally four times daily for 14 days
  • Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
  • Erythromycin ethylsuccinate 400 mg orally four times daily for 14 days 3, 4

Critical pregnancy considerations:

  • Erythromycin estolate is contraindicated due to hepatotoxicity risk 3, 4
  • Test-of-cure is mandatory at minimum 3 weeks after treatment completion to identify persistent/repeat infection and prevent neonatal transmission 7
  • Amoxicillin shows equivalent efficacy to erythromycin with better tolerability 6
  • Recent evidence supports azithromycin as safe and effective (97% efficacy) in pregnancy 5

Partner Management

All sexual partners within 60 days preceding symptom onset or diagnosis must be evaluated and treated 1. For symptomatic patients, extend this to 30 days before symptom onset 4.

Key partner treatment principles:

  • Treat the most recent partner even if contact occurred >60 days prior 3, 1
  • Partners should receive the same regimen as the index patient
  • Both patient and partners must abstain from sexual intercourse for 7 days after single-dose therapy OR until completion of 7-day regimen 1
  • Abstinence continues until all partners complete treatment to prevent reinfection 1

Follow-Up and Retesting

Test-of-Cure

Not routinely recommended for non-pregnant patients treated with doxycycline or azithromycin unless 1:

  • Symptoms persist
  • Reinfection suspected
  • Compliance questionable
  • Patient is pregnant (mandatory at ≥3 weeks post-treatment) 7

Testing pitfalls to avoid:

  • Do not test <3 weeks after treatment completion - yields false-positive results from dead organisms with NAATs 1
  • False-negatives can occur from low organism numbers 3, 1

Repeat Testing for Reinfection

Retest all women approximately 3 months after treatment 1. This is distinct from test-of-cure and addresses the high reinfection rates (not treatment failure).

Rationale: Repeat infections confer elevated risk for PID and complications compared to initial infection. Most post-treatment infections result from untreated partners or new infected partners 1.

Also retest when patients return for any medical care within 3-12 months, regardless of reported partner treatment status 1.

Special Populations

HIV-Infected Patients

Treat identically to HIV-negative patients - no regimen modifications needed 2, 4, 3, 2.

Coinfection with Gonorrhea

Presumptive chlamydia treatment is appropriate for all patients treated for gonorrhea due to high coinfection rates 4, 2, 1, 2.

Practical Implementation

Maximize compliance by:

  • Dispensing medications on-site
  • Directly observing the first dose
  • Using single-dose azithromycin for populations with poor follow-up 1

Common pitfall: Failing to ensure partner treatment leads to reinfection and continued transmission. The patient must abstain from intercourse until both they AND all partners complete treatment 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.